Clinical Trial Update: A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating long-term outcomes after treatment with ABT-450/r/ABT-267 and ABT-333 with or without ribavirin in genotype 1 chronic hepatitis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-333 (ABT-333)
• ABT-450/r/ABT-267
• Ribavirin (ribavirin)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C Virus (HCV) Infection Genotype 1 | Phase 3 | Status: COMPLETED | Results posted: 2022-04-06